Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Mayo Foundation for Medical Education and Research

Leland Stanford Junior University

Other

Syntex LLC

3100 Central Expressway LLC

Piksci Inc.

Robert J Greenhouse

Joseph M Muchowski

Saul Jaime-Figueroa

William L Thomas

Ralph New Harris, Iii

David Bruce Repke

Kevin Lloyd Greenman

Russell Stephen Stabler

James M Kress

Eugenia Trushina

Lee Allen Flippin

Shu-Hai Zhao

Jacob Berger

Aubry Kern Miller

Nikolai Sepetov

Lubica Raptova

Klaus Kurt Weinhardt

David George Putman

Yanzhou Liu

Jurg R Pfister

Robert James Weikert

John M Young

Angel Guzman

Jack Ackrell

Karin Ann Stein

D V Murthy

Alexander Keith Stewart

Sergei Romanov

Artem Plekhov

Richard Neil Zare

Counde O'Yang

Steven R Schow

Stephen Matthew Lynch

Tsung-tee Li

Dean W Felsher

Deborah Carol Reuter

Tsung-Tee Li

Steven Richards

David Loughhead

Brian Rich

Katherine Margulis

Feng Jin

Anthony J Ricci

Arvin Gouw

Wen Yang

Alan G Cheng

Zhiwei Tong

Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: wherein X is absent, CH, or C(O); Ris H, OH, CN, NO, halo, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, Ccycloalkyl, amino, Calkylamino, or di(Calkyl)amino; Ris H or Calkyl; Ris H, Calkyl, —C(O)(Calkyl), or —C(O)O(Calkyl); Ris Ccycloalkyl, Caryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected Rgroups; and Ris OH, CN, NO, halo, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, Ccycloalkyl, amino, Calkylamino, or di(Calkyl)amino.

Compounds for modulating mitochondrial function

A compound and/or a pharmaceutically acceptable salt thereof has the following formula A: These compounds can be PIKfyve kinase inhibitors.

Fused triazolo-pyrimidine compounds having useful pharmaceutical application

Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome and hyperlipidemia.

Inhibitors of phospholipid synthesis and methods of use

Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: wherein X is absent, CH, or C(O); Ris H, OH, CN, NO, halo, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, Ccycloalkyl, amino, Calkylamino, or di(Calkyl)amino; Ris H or Calkyl; Ris H, Calkyl, &#x2014;C(O)(Calkyl), or &#x2014;C(O)O(Calkyl); Ris Ccycloalkyl, Caryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected Rgroups; and Ris OH, CN, NO, halo, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, Ccycloalkyl, amino, Calkylamino, or di(Calkyl)amino.

A compound and/or a pharmaceutically acceptable salt thereof has the following formula A: These compounds can be PIKfyve kinase inhibitors. 

This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Inhibiting G protein coupled receptor 6 kinase polypeptides

Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Tetralin and indane derivatives and uses thereof

This disclosure relates generally to aminoglycoside derivatives of Formula (I) as described herein. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating bacterial infections by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Aminoglycoside antibiotics with reduced ototoxicity

Compounds of formula I: or pharmaceutically acceptable salts, solvates or prodrugs thereof,

3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors

This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.

Imidazolinylmethyl aryl sulfonamide

Growing community of inventors

Cupertino, CA, United States of America

Robert J Greenhouse